|
1
|
Youlden DR, Cramb SM, Dunn NA, Muller JM,
Pyke CM and Baade PD: The descriptive epidemiology of female breast
cancer: an international comparison of screening, incidence,
survival and mortality. Cancer Epidemiol. 36:237–248. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Isakoff SJ: Triple-negative breast cancer:
role of specific chemotherapy agents. Cancer J. 16:53–61. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fukuda H, Sano N, Muto S and Horikoshi M:
Simple histone acetylation plays a complex role in the regulation
of gene expression. Brief Funct Genomic Proteomic. 5:190–208. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Federico M and Bagella L: Histone
deacetylase inhibitors in the treatment of hematological
malignancies and solid tumors. J Biomed Biotechnol. 2011:475642011.
View Article : Google Scholar
|
|
5
|
Khan O and La Thangue NB: HDAC inhibitors
in cancer biology: emerging mechanisms and clinical applications.
Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar
|
|
6
|
Rikiishi H: Autophagic and apoptotic
effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol.
2011:8302602011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mork CN, Faller DV and Spanjaard RA: A
mechanistic approach to anticancer therapy: targeting the cell
cycle with histone deacetylase inhibitors. Curr Pharm Des.
11:1091–1104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alao JP, Stavropoulou AV, Lam EW and
Coombes RC: Role of glycogen synthase kinase 3 beta (GSK3beta) in
mediating the cytotoxic effects of the histone deacetylase
inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol
Cancer. 5:402006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee YJ, Won AJ, Lee J, Jung JH, Yoon S,
Lee BM and Kim HS: Molecular mechanism of SAHA on regulation of
autophagic cell death in tamoxifen-resistant MCF-7 breast cancer
cells. Int J Med Sci. 9:881–893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ning L, Jaskula-Sztul R, Kunnimalaiyaan M
and Chen H: Suberoyl bishydroxamic acid activates notch1 signaling
and suppresses tumor progression in an animal model of medullary
thyroid carcinoma. Ann Surg Oncol. 15:2600–2605. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
You BR and Park WH: Suberoyl bishydroxamic
acid inhibits the growth of A549 lung cancer cells via
caspase-dependent apoptosis. Mol Cell Biochem. 344:203–210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhuang ZG, Fei F, Chen Y and Jin W:
Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of
MCF-7 breast cancer cells. Acta Pharmacol Sin. 29:1459–1466. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hrabeta J, Stiborova M, Adam V, Kizek R
and Eckschlager T: Histone deacetylase inhibitors in cancer
therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech
Repub 2013. 158:161–169. 2014.
|
|
14
|
Yoon MK, Mitrea DM, Ou L and Kriwacki RW:
Cell cycle regulation by the intrinsically disordered proteins p21
and p27. Biochem Soc Trans. 40:981–988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang D, Wang X, Liu X and Li F: Gene
delivery of cyclin-dependent kinase inhibitors p21 (Waf1) and p27
(Kip1) suppresses proliferation of MCF-7 breast cancer cells in
vitro. Breast Cancer. 21:614–623. 2013. View Article : Google Scholar
|
|
16
|
Wei M, Liu B, Gu Q, Su L, Yu Y and Zhu Z:
Stat6 cooperates with Sp1 in controlling breast cancer cell
proliferation by modulating the expression of p21 (Cip1/WAF1) and
p27 (Kip1). Cell Oncol (Dordr). 36:79–93. 2013. View Article : Google Scholar
|
|
17
|
Greenblatt DY, Cayo M, Ning L, et al:
Suberoyl bishydroxamic acid inhibits cellular proliferation by
inducing cell cycle arrest in carcinoid cancer cells. J
Gastrointest Surg. 11:1515–1520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L and Yu J: Role of apoptosis in
colon cancer biology, therapy, and prevention. Curr Colorectal
Cancer Rep. 9:2013. View Article : Google Scholar
|
|
19
|
Beckta JM, Ahmad SF, Yang H and Valerie K:
Revisiting p53 for cancer-specific chemo- and radiotherapy: Ten
years after. Cell Cycle. 13:2014. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cregan SP, MacLaurin JG, Craig CG,
Robertson GS, Nicholson DW, Park DS and Slack RS: Bax-dependent
caspase-3 activation is a key determinant in p53-induced apoptosis
in neurons. J Neurosci. 19:7860–7869. 1999.PubMed/NCBI
|
|
21
|
Wang J, Kim TH, Ahn MY, et al: Sirtinol, a
class III HDAC inhibitor, induces apoptotic and autophagic cell
death in MCF-7 human breast cancer cells. Int J Oncol.
41:1101–1109. 2012.PubMed/NCBI
|
|
22
|
Danial NN: BCL-2 family proteins: critical
checkpoints of apoptotic cell death. Clin Cancer Res. 13:7254–7263.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen S, Dai Y, Pei XY and Grant S: Bim
upregulation by histone deacetylase inhibitors mediates
interactions with the Bcl-2 antagonist ABT-737: evidence for
distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol.
29:6149–6169. 2009. View Article : Google Scholar : PubMed/NCBI
|
